Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 8: From prodrome to psychosis: early-onset schizophrenia
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
Which of the following is U.S. Food and Drug Administration (FDA)-approved for the treatment of schizophrenia in adolescents?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 119 - 136Publisher: Cambridge University PressPrint publication year: 2023
References
Arman, S., Haghshenas, M. Metabolic effects of adding topiramate on aripiprazole in bipolar patients aged between 6–18 years: a randomized, double-blind, placebo-controlled trial. J Res Med Sci 2022; 27(1): 23. https://doi.org/10.4103/jrms.jrms_672_21Google Scholar
Bosnjak Kuharic, D., Kekin, I., Hew, J., Rojnic Kuzman, M., Puljak, L. Interventions for prodromal stage of psychosis. Cochrane Database Syst Rev 2019; 2019(11): CD012236. https://doi.org/10.1002/14651858.CD012236.pub2Google Scholar
DelBello, M. P., Strawn, J. R., Duran, L. P. 1.6 Recognition and management of second-generation antipsychotic-associated adverse effects. J Am Acad Child Adolesc Psychiatry 2017; 56(10): S135. https://doi.org/10.1016/j.jaac.2017.07.509Google Scholar
Freeman, M. P., McInerney, K., Sosinsky, A. Z., Kwiatkowski, M. A., Cohen, L. S. Omega-3 fatty acids for atypical antipsychotic-associated hypertriglyceridemia. Ann Clin Psychiatry 2015; 27(3): 197–202. https://doi.org/10.1016/j.jaac.2016.12.013Google Scholar
McClellan, J., Stock, S.; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2013; 52(9): 976–90. https://doi.org/10.1016/j.jaac.2013.02.008Google Scholar
Pagsberg, A. K., Tarp, S., Glintborg, D., et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 2017; 56(3): 191–202. https://doi.org/10.1016/j.jaac.2016.12.013Google Scholar
Savitz, A., Lane, R., Nuamah, I., et al. Long-term safety of paliperidone extended release in adolescents with schizophrenia: an open-label, flexible dose study. J Child Adolesc Psychopharmacol 2015; 25(7): 548–57. https://doi.org/10.1089/cap.2014.0130Google Scholar
Singh, J., Robb, A., Vijapurkar, U., Nuamah, I., Hough, D. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biological Psychiatry 2011; 70(12): 1179–87. https://doi.org/10.1016/j.biopsych.2011.06.021Google Scholar
Siskind, D., Hahn, M., Correll, C. U., et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab 2019; 21(2): 293–302. https://doi.org/10.1111/dom.13522Google Scholar
Siskind, D. J., Russell, A. W., Gamble, C., et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab 2018; 20(4): 1050–55. https://doi.org/10.1111/dom.13167Google Scholar
Strawn, J. R., DelBello, M. P. 59.4 Recognizing and managing side effects of second-generation antipsychotics. J Am Acad Child Adolesc Psychiatry 2018; 57(10): S85. https://doi.org/10.1016/j.jaac.2018.07.358Google Scholar
Sunshine, A., McClellan, J. Practitioner Review: psychosis in children and adolescents. J Child Psychol Psychiatry. 2023. doi: 10.1111/jcpp.13777. Epub ahead of print. PMID: 36878476.Google Scholar
Xu, X., Shao, G., Zhang, X., et al. The efficacy of nutritional supplements for the adjunctive treatment of schizophrenia in adults: a systematic review and network meta-analysis. Psychiatry Res 2022; 311: 114500. https://doi.org/10.1016/j.psychres.2022.114500Google Scholar